Edwards Lifesciences Net Income From Continuing Ops Over Time
| EW Stock | USD 82.10 0.55 0.67% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Edwards Lifesciences Performance and Edwards Lifesciences Correlation. What growth prospects exist in Health Care Equipment & Supplies sector? Can Edwards capture new markets? Factors like these will boost the valuation of Edwards Lifesciences. Projected growth potential of Edwards fundamentally drives upward valuation adjustments. Valuation analysis balances hard financial data with qualitative growth assessments. While each Edwards Lifesciences valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Quarterly Earnings Growth (0.90) | Earnings Share 2.22 | Revenue Per Share | Quarterly Revenue Growth 0.147 | Return On Assets |
Investors evaluate Edwards Lifesciences Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Edwards Lifesciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. External factors like market trends, sector rotation, and investor psychology can cause Edwards Lifesciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Edwards Lifesciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Edwards Lifesciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Edwards Lifesciences' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Edwards Lifesciences Corp and related stocks such as Becton Dickinson, Cardinal Health, and Bruker Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BDX | 1.3 B | 929 M | 929 M | 1.2 B | 695 M | 976 M | 1.1 B | 311 M | 1.2 B | 874 M | 2.1 B | 1.6 B | 1.5 B | 1.7 B | 1.7 B | 1.9 B | 1.4 B |
| CAH | 587 M | 1.1 B | 335 M | 1.2 B | 1.2 B | 1.4 B | 1.3 B | (715 M) | 2.1 B | (3.7 B) | 612 M | (932 M) | 262 M | 853 M | 1.6 B | 1.4 B | 1.5 B |
| BRKR | 94 M | 94 M | 81.8 M | 81.8 M | 59.6 M | 104.9 M | 154.5 M | 80.3 M | 181 M | 198 M | 168.9 M | 280.6 M | 298.5 M | 322.2 M | 113.8 M | 130.9 M | 180.9 M |
| ARGX | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (12.5 M) | (16.6 M) | (21.4 M) | (28.1 M) | (66.6 M) | (163 M) | (528.9 M) | (408.3 M) | (709.6 M) | (295.1 M) | 833 M | 749.7 M | 787.2 M |
| VEEV | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 40.4 M | 54.5 M | 68.8 M | 142 M | 229.8 M | 301.1 M | 380 M | 427.4 M | 487.7 M | 525.7 M | 714.1 M | 821.3 M | 862.3 M |
| A | (31 M) | 1.2 B | 724 M | 504 M | 438 M | 462 M | 684 M | 316 M | 1.1 B | 719 M | 1.2 B | 1.3 B | 1.2 B | 1.3 B | 1.3 B | 1.5 B | 908 M |
| STE | 129.4 M | 129.4 M | 129.4 M | 129.4 M | 135.1 M | 111.6 M | 110.6 M | 291.6 M | 305.1 M | 407.8 M | 396.9 M | 242.9 M | 105.8 M | 553.3 M | 611.6 M | 703.3 M | 738.5 M |
| ALC | 256 M | 256 M | 256 M | 256 M | 256 M | 256 M | 256 M | 256 M | (315 M) | (656 M) | (531 M) | 376 M | 335 M | 974 M | 1 B | 1.2 B | 1.2 B |
| HLN | 687 M | 687 M | 687 M | 687 M | 687 M | 687 M | 687 M | 687 M | 687 M | 687 M | 1.2 B | 1.4 B | 1.1 B | 1.1 B | 1.5 B | 1.7 B | 1.3 B |
| DXCM | (44.7 M) | (44.7 M) | (54.5 M) | (29.8 M) | (22.4 M) | (57.6 M) | (65.6 M) | (50.2 M) | (127.1 M) | 101.1 M | 493.6 M | 154.7 M | 341.2 M | 541.5 M | 576.2 M | 662.6 M | 695.8 M |
Edwards Lifesciences Corp and related stocks such as Becton Dickinson, Cardinal Health, and Bruker Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Edwards Lifesciences Corp | EW |
| Classification | Healthcare |
| Business Address | One Edwards Way, |
| Exchange | New York Stock Exchange |
USD 82.1
Additional Tools for Edwards Stock Analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.